ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025
[The partial cure represents an intermediate endpoint on the path to a functional cure, not an ideal endpoint].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A partial cure, defined as HBsAg <100 IU/mL and HBV DNA below the lower limit of quantification (i.e., <10 IU/mL) at 24 weeks off-treatment, is an intermediate endpoint on the pathway to a functional cure, not a realistic goal. Patient with chronic hepatitis B achieved a partial cure have good outcomes. qHBsAg in combination with HBV RNA, hepatitis B core related antigen, LHBs, MHBs and qAnti-HBc may predict virological and clinical relapses of patients with a partial cure. The patients achieved partial cure should be monitored closely. Retreatment is necessary for patients who experience a virus-dominated hepatic flare after discontinuation of therapy, whereas it is not for those with a host-dominated flare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.